Imper Vera 4

What Happened

• Imper Vera, a director of Cytek Biosciences, had two RSU awards (33,333 and 18,261 shares) reported as acquired and immediately vested on June 10, 2026, totaling 51,594 RSUs (priced at $0.00 as compensation).
• The filing also shows an exercise/conversion of a derivative for 43,973 shares on June 10, 2026 (reported as both acquired and disposed the same day). Prices reported are $0.00 or N/A and no cash value is shown in the filing.
• These transactions are primarily compensation-related (RSU vesting) and a same-day conversion/disposition (commonly a sell-to-cover or withholding settlement mechanism), rather than an open‑market purchase or investment.

Key Details

• Transaction date: June 10, 2026; Filing date: June 12, 2026 (timely under Section 16 rules).
• RSU awards: 33,333 and 18,261 shares granted/vested — 100% vested on June 10, 2026 (Footnotes F1, F4).
• Derivative conversion/exercise: 43,973 shares both acquired and disposed on June 10, 2026 (reported M code; Footnote F3 relates to option vesting schedules).
• Prices/values reported: RSUs at $0.00 (compensation); the conversion/disposition shows $0.00 or N/A in the filing — no cash proceeds shown in the excerpt.
• Shares owned after transaction: not specified in the provided excerpt — see the full Form 4 for total beneficial ownership.
• Filing status: Timely (filed two days after the transaction).

Context

• RSU vesting is compensation and does not represent an open‑market purchase; it increases insider holdings unless shares are withheld to cover taxes.
• The equal same‑day acquisition and disposition of 43,973 derivative shares indicates an immediate settlement action (e.g., withholding/sell‑to‑cover), but the Form 4 excerpt does not specify the exact settlement mechanics — see the full filing for details.